[go: up one dir, main page]

WO2004098534A3 - Techniques d'apport de modulateurs angiogeniques au moyen de poxvirus - Google Patents

Techniques d'apport de modulateurs angiogeniques au moyen de poxvirus Download PDF

Info

Publication number
WO2004098534A3
WO2004098534A3 PCT/US2004/005376 US2004005376W WO2004098534A3 WO 2004098534 A3 WO2004098534 A3 WO 2004098534A3 US 2004005376 W US2004005376 W US 2004005376W WO 2004098534 A3 WO2004098534 A3 WO 2004098534A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pox viruses
modulators
angiogenic modulators
delivering angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/005376
Other languages
English (en)
Other versions
WO2004098534A2 (fr
Inventor
Dennis L Panicali
Gail P Mazzara
Linda R Gritz
Patricia Greenhalgh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therion Biologics Corp
Original Assignee
Therion Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therion Biologics Corp filed Critical Therion Biologics Corp
Publication of WO2004098534A2 publication Critical patent/WO2004098534A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004098534A3 publication Critical patent/WO2004098534A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des techniques d'apport de modulateurs angiogéniques à un individu, des construits comprenant un poxvirus de recombinaison lequel comprenant au moins une séquence d'acide nucléique codante pour un agent modulateur angiogénique et des techniques de traitement de pathologies associées à une angiogenèse anormale au moyen de ces poxvirus de recombinaison.
PCT/US2004/005376 2003-02-24 2004-02-24 Techniques d'apport de modulateurs angiogeniques au moyen de poxvirus Ceased WO2004098534A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44972003P 2003-02-24 2003-02-24
US60/449,720 2003-02-24

Publications (2)

Publication Number Publication Date
WO2004098534A2 WO2004098534A2 (fr) 2004-11-18
WO2004098534A3 true WO2004098534A3 (fr) 2006-01-26

Family

ID=33434896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005376 Ceased WO2004098534A2 (fr) 2003-02-24 2004-02-24 Techniques d'apport de modulateurs angiogeniques au moyen de poxvirus

Country Status (1)

Country Link
WO (1) WO2004098534A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754221B2 (en) 2003-06-18 2010-07-13 Genelux Corporation Microorganisms for therapy
US9005602B2 (en) 2006-10-16 2015-04-14 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004291024B2 (en) * 2003-02-20 2009-09-17 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel insertion sites in pox vectors
WO2008142479A2 (fr) † 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Sites intergéniques entre des gènes conservés dans le génome du virus de la vaccine vaccinia ankara modifié (mva)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6258791B1 (en) * 1997-05-29 2001-07-10 Transgene S.A. Combination product for enhanced gene delivery comprising a hyaluronidase
US20020025941A1 (en) * 2000-06-14 2002-02-28 Olivier Meyer Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6258791B1 (en) * 1997-05-29 2001-07-10 Transgene S.A. Combination product for enhanced gene delivery comprising a hyaluronidase
US20020025941A1 (en) * 2000-06-14 2002-02-28 Olivier Meyer Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754221B2 (en) 2003-06-18 2010-07-13 Genelux Corporation Microorganisms for therapy
US8221769B2 (en) 2003-06-18 2012-07-17 Genelux Corporation Microorganisms for therapy
US8323959B2 (en) 2003-06-18 2012-12-04 Genelux Corporation Microorganisms for therapy
US8784836B2 (en) 2003-06-18 2014-07-22 Genelux Corporation Microorganisms for therapy
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy
US9005602B2 (en) 2006-10-16 2015-04-14 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
WO2004098534A2 (fr) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2004112831A3 (fr) Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique
WO2003012057A3 (fr) Modulation antisens de l'expression du serum amyloide a4
ATE316576T1 (de) Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
WO2003011887A3 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2002092772A3 (fr) Modulation antisens de l'expression de ptp1b
WO2003014307A3 (fr) Modulation antisens de l'expression de l'apolipoproteine (a)
WO2010040023A3 (fr) Méthodes et compositions d’administration de protéines
MY169352A (en) Vaccine against rsv
WO2010039224A3 (fr) Séquences du virus syncytial respiratoire (rsv) destinées à l'expression de protéines et aux vaccins
WO2002024234A3 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
WO2003010284A3 (fr) Modulation antisens de l'expression de la proteine reactive c
WO2003052072A3 (fr) Modulation antisens de l'expression du recepteur alpha d'oestrogene
WO2005049850A3 (fr) Compositions et procedes d'administration de sequence d'acides nucleiques systemiques
SI1881845T1 (sl) Cepiva proti virusu Nipah
WO2003022222A3 (fr) Modulation anti-sens de l'expression d'une proteine kinase r
NZ597773A (en) Raccoon poxvirus expressing rabies glycoproteins
WO2003023040A3 (fr) Mutants du virus de la vaccine obtenus par inactivation de mva-e3l et leur utilisation
WO2003054154A3 (fr) Modulation antisens de l'expression de la mucine 1, transmembranaire
WO2004098534A3 (fr) Techniques d'apport de modulateurs angiogeniques au moyen de poxvirus
WO2003053341A3 (fr) Modulation antisens de l'expression de ship-1
WO2006058231A3 (fr) Vecteurs viraux
WO2002062954A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-beta
WO2002062951A3 (fr) Modulation antisens de l'expression de caseine kinase 2-alpha prime
WO2003050244A3 (fr) Modulation antisens de l'expression de recepteur etbr-lp-2 couple aux proteines g
WO2003052062A3 (fr) Modulation antisens de l'expression de cd36l1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase